.png){kind=logo}
FDA Finalizes Mandatory Cosmetics Recall Guidance: What K-Beauty Brands Entering the U.S. Should Know
The U.S. Food and Drug Administration (FDA) has finalized its guidance on Mandatory Cosmetics Recalls, providing more clarity on how the agency may exercise its recall authority under the Modernization of Cosmetics Regulation Act of 2022 (MoCRA).
The final guidance, issued in October 2026, addresses common questions about the criteria, process, and expectations surrounding mandatory recalls of cosmetic products.
For Korean beauty brands planning to enter the U.S. market, the guidance is worth paying attention to—not because FDA expects every cosmetic recall to become mandatory, but because it highlights how product safety and compliance risks can extend across the entire product lifecycle.
What Is a Mandatory Cosmetic Recall?
Historically, most cosmetic recalls in the U.S. have been conducted voluntarily.
MoCRA changed the regulatory framework by adding Section 611 to the Federal Food, Drug, and Cosmetic Act, giving FDA authority to order a responsible person to cease distribution and recall a cosmetic when certain conditions are met.
FDA continues to state that it expects most violative cosmetics to be voluntarily recalled.
However, when the statutory criteria are satisfied, FDA may move beyond a voluntary recall.
When Can FDA Order a Mandatory Recall?
According to the final guidance, FDA must determine that two conditions are met:
There is a reasonable probability that the cosmetic is adulterated or misbranded; and
There is a reasonable probability that use of or exposure to the cosmetic will cause serious adverse health consequences or death (SAHCOD).
This is an important distinction.
A compliance issue by itself does not automatically mean FDA will order a mandatory recall. The agency's mandatory recall authority is tied to the combination of a potential adulteration or misbranding issue and a reasonable probability of serious harm.
What Can FDA Consider?
The guidance explains that FDA may consider a broad range of evidence when evaluating whether to move forward with a mandatory recall.
This can include:
Significant safety observations during facility inspections
Testing of raw materials or finished cosmetic products
Environmental or facility sample results
Epidemiological information
Serious adverse event data
Consumer and trade complaints
The vulnerability of the population using the product
Whether the responsible person has failed to voluntarily cease distribution or initiate a voluntary recall
This broader view is particularly relevant for brands that manufacture products overseas and distribute them throughout the U.S.
A product issue may not originate from a single point in the supply chain. It can involve formulation, raw materials, manufacturing conditions, labeling, claims, or post-market information.
Safety Substantiation Matters
One of the particularly important points in the guidance is FDA's discussion of adulteration.
Under the guidance, a cosmetic may be considered adulterated if the product, including its ingredients, does not have adequate substantiation for safety as defined under MoCRA.
This reinforces an important principle for brands:
Having a product on the market is not the same as having a well-documented safety foundation for that product.
For brands entering the U.S., safety substantiation should therefore be considered during product development—not only after a regulatory question arises.
Labeling and Claims Can Also Matter
The guidance also addresses misbranding.
Among other circumstances, a cosmetic may be considered misbranded if its labeling is false or misleading, or if required information is not properly presented.
For K-Beauty brands, this is particularly relevant because products developed for the Korean market may use claims, terminology, or positioning that do not translate directly into the U.S. regulatory framework.
A claim that appears familiar or acceptable in one market may need to be reconsidered when the same product is introduced in the United States.
This is especially important for products positioned around benefits such as skin treatment, brightening, anti-aging, acne, or other functions that may raise questions about whether a product remains a cosmetic or falls under drug requirements.
What Happens Before a Mandatory Recall?
FDA's process does not begin immediately with a recall order.
If FDA determines that the criteria for mandatory recall are met, the agency will first provide the responsible person with an opportunity to voluntarily cease distribution and recall the product.
If the responsible person does not voluntarily take the requested action within the time and manner prescribed by FDA, FDA may issue an order requiring the responsible person to immediately cease distribution.
The responsible person is also provided an opportunity for an informal hearing. If a hearing is granted, it must be held no later than 10 days after the order is issued.
Following the hearing, FDA may:
Vacate the order
Continue the cease-distribution order
Amend the order to require a recall
If FDA ultimately orders a recall, the responsible person may also be required to notify appropriate parties, including manufacturers, distributors, importers, retailers, and the public.
What Does This Mean for K-Beauty Brands?
The bigger takeaway is not that mandatory recalls will become routine.
It is that U.S. cosmetic compliance increasingly needs to be considered as an end-to-end process.
For a Korean brand entering the U.S., that process can include:
Product concept → Formula → Claims → Safety substantiation → Manufacturing → Labeling → U.S. launch → Distribution → Post-market monitoring
A compliance review performed just before shipment may identify obvious problems, but it may not address risks that were built into the product from the beginning.
For brands working with Korean OEM/ODM manufacturers, this makes early communication between the brand, manufacturer, and U.S. regulatory team especially important.
The goal is not simply to get a product into the U.S.
The goal is to build a product and launch process that can support the product after it reaches the U.S. market.
Final Takeaway
FDA's October 2026 final guidance provides a clearer picture of how the agency may exercise its mandatory cosmetics recall authority under MoCRA.
For K-Beauty brands, the practical lesson is straightforward:
U.S. compliance should be part of the launch strategy—not a final checkpoint before shipment.
As Korean beauty continues to expand in the U.S., brands that build regulatory thinking into sourcing, formulation, claims, manufacturing, and launch planning will be better positioned to manage compliance risks as they grow.
For inquiries or expert assistance, please contact us today.
CONTACT US
Office: 1-909-493-3276
Email: ask@provisionfda.com